Deoxyspergualin: mechanism of action and pharmacokinetics.
Ramos
E L
EL
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA.
Nadler
S G
SG
Grasela
D M
DM
Kelley
S L
SL
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002467:Cell Nucleus / Q000502:physiology; D006146:Guanidines / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology; D008954:Models, Biological; D009103:Multiple Sclerosis / Q000188:drug therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D006146:Guanidines; D007166:Immunosuppressive Agents; D016328:NF-kappa B; C037258:gusperimus